Literature DB >> 9217879

The diabetic heart is more sensitive to ischemic injury.

D J Paulson1.   

Abstract

Clinical studies have suggested that the diabetic heart is more sensitive to ischemic injury than the non-diabetic heart. However, results from a number of experimental studies using animal models of diabetes reported no change, increased or decreased sensitivity to ischemia. The purpose of this review is to discuss the possible explanations for this apparent discrepancy. Analysis of the conflicting literature on this subject reveals a pattern which suggests that the disparity of experimental findings stems from differences in the duration and severity of the diabetic state, the ischemic flow rate and whether fatty acids are provided as an exogenous substrate. It appears that short-term or mild diabetes is associated with decreased sensitivity to zero-flow ischemic injury. However, as the duration or severity of diabetes increases, this beneficial effect disappears. The diabetic heart also appears to be more vulnerable to injury during low-flow ischemia and when elevated fatty acids are present.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9217879     DOI: 10.1016/s0008-6363(97)00018-7

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  37 in total

1.  Propionyl-L-carnitine effects on postischemic recovery of heart function and substrate oxidation in the diabetic rat.

Authors:  T L Broderick; W Driedzic; D J Paulson
Journal:  Mol Cell Biochem       Date:  2000-03       Impact factor: 3.396

2.  Upregulation of eNOS and unchanged energy metabolism in increased susceptibility of the aging type 2 diabetic GK rat heart to ischemic injury.

Authors:  Martine Desrois; Kieran Clarke; Carole Lan; Christiane Dalmasso; Mark Cole; Bernard Portha; Patrick J Cozzone; Monique Bernard
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-08-20       Impact factor: 4.733

Review 3.  Autophagy, myocardial protection, and the metabolic syndrome.

Authors:  Zoltan Giricz; Robert M Mentzer; Roberta A Gottlieb
Journal:  J Cardiovasc Pharmacol       Date:  2012-08       Impact factor: 3.105

Review 4.  Metabolic abnormalities in the diabetic heart.

Authors:  Gary D Lopaschuk
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

Review 5.  Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment.

Authors:  Inês Falcão-Pires; Adelino F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

6.  Subcellular mechanisms of adaptation in the diabetic myocardium: Relevance to ischemic preconditioning in the nondiseased heart.

Authors:  T Ravingerová; A Adameová; J Matejíková; T Kelly; M Nemčeková; J Kucharská; O Pecháňová; A Lazou
Journal:  Exp Clin Cardiol       Date:  2010

Review 7.  Cardiomyocyte apoptosis in animal models of obesity.

Authors:  Premal S Trivedi; Lili A Barouch
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

8.  Diabetes and mitochondrial oxidative stress: a study using heart mitochondria from the diabetic Goto-Kakizaki rat.

Authors:  Dario Loureiro Santos; Carlos Marques Palmeira; Raquel Seiça; José Dias; José Mesquita; António Joaquim Moreno; Maria Sancha Santos
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

9.  Targeted Modification of Mitochondrial ROS Production Converts High Glucose-Induced Cytotoxicity to Cytoprotection: Effects on Anesthetic Preconditioning.

Authors:  Filip Sedlic; Maria Y Muravyeva; Ana Sepac; Marija Sedlic; Anna Marie Williams; Meiying Yang; Xiaowen Bai; Zeljko J Bosnjak
Journal:  J Cell Physiol       Date:  2016-06-21       Impact factor: 6.384

10.  Sustained cardiomyocyte apoptosis and left ventricular remodelling after myocardial infarction in experimental diabetes.

Authors:  T Bäcklund; E Palojoki; A Saraste; A Eriksson; P Finckenberg; V Kytö; P Lakkisto; E Mervaala; L-M Voipio-Pulkki; M Laine; I Tikkanen
Journal:  Diabetologia       Date:  2004-01-13       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.